Shyam Sundar1, Jaya Chakravarty. 1. Banaras Hindu University, Institute of Medical Sciences, Department of Medicine, Varanasi-221005, India. drshyamsundar@hotmail.com
Abstract
BACKGROUND: The treatment options for leishmaniasis are limited. Most of the drugs available need parenteral administration, are toxic, require monitoring and have a prolonged treatment duration. All these factors increase the cost of the treatment. The development of resistance to pentavalent antimonials in patients with visceral leishmaniasis in North Bihar, India, has added another dimension to the problem. OBJECTIVE: To summarise the pharmacological and clinical data on antileishmanial activity of paromomycin and discuss the impact this agent may have on present treatment regimens. METHODS: A literature search on paromomycin and leishmaniasis was done on PubMed and through Google. RESULTS: Paromomycin, with its excellent efficacy, low cost, shorter duration of administration and good safety profile, has the potential to be used as a first-line drug.
BACKGROUND: The treatment options for leishmaniasis are limited. Most of the drugs available need parenteral administration, are toxic, require monitoring and have a prolonged treatment duration. All these factors increase the cost of the treatment. The development of resistance to pentavalent antimonials in patients with visceral leishmaniasis in North Bihar, India, has added another dimension to the problem. OBJECTIVE: To summarise the pharmacological and clinical data on antileishmanial activity of paromomycin and discuss the impact this agent may have on present treatment regimens. METHODS: A literature search on paromomycin and leishmaniasis was done on PubMed and through Google. RESULTS:Paromomycin, with its excellent efficacy, low cost, shorter duration of administration and good safety profile, has the potential to be used as a first-line drug.
Authors: Luis Carvalho; Juan Román Luque-Ortega; Carmen López-Martín; Santiago Castanys; Luis Rivas; Francisco Gamarro Journal: Antimicrob Agents Chemother Date: 2011-06-13 Impact factor: 5.191
Authors: Michel Muálem de Moraes Alves; Daniel Dias Rufino Arcanjo; Kayo Alves Figueiredo; Jéssica Sara de Sousa Macêdo Oliveira; Felipe José Costa Viana; Elvilene de Sousa Coelho; Glaucia Lais Nunes Lopes; Juan Carlos Ramos Gonçalves; André Luís Menezes Carvalho; Márcia Dos Santos Rizzo; Mariana Helena Chaves; Ivete Lopes de Mendonça; Fernando Aécio de Amorim Carvalho Journal: Antimicrob Agents Chemother Date: 2020-11-17 Impact factor: 5.191
Authors: Patrick O Sakyi; Richard K Amewu; Robert N O A Devine; Emahi Ismaila; Whelton A Miller; Samuel K Kwofie Journal: Nat Prod Bioprospect Date: 2021-07-14